Alnylam Pharmaceuticals Q1 2025 Update
Ticker: ALNY · Form: 10-Q · Filed: May 1, 2025 · CIK: 1178670
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Alnylam Q1 2025 10-Q filed. Financials and operations detailed.
AI Summary
Alnylam Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The filing details financial performance and business operations for the first quarter of 2025, comparing it to the same period in 2024. Key financial data and operational segments are presented, including product and collaboration revenues.
Why It Matters
This filing provides investors with an update on Alnylam's financial health and operational progress in early 2025, crucial for understanding the company's trajectory in the competitive pharmaceutical market.
Risk Assessment
Risk Level: medium — Quarterly reports can reveal shifts in financial performance or strategic direction that may impact stock price.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-12-31 — Previous Fiscal Year End (Provides a comparison point for year-end financial status.)
- 2024-01-01 2024-03-31 — Q1 2024 Period (Financial data for the first quarter of the previous year.)
- 2025-01-01 2025-03-31 — Q1 2025 Period (Financial data for the first quarter of the current year.)
Key Players & Entities
- ALNYLAM PHARMACEUTICALS, INC. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250501 (date) — Filing Date
- 675 WEST KENDALL STREET (address) — Company Business Address
- CAMBRIDGE, MA (location) — Company Business Location
FAQ
What were Alnylam's total revenues for the first quarter of 2025?
The filing indicates financial data for the period 2025-01-01 to 2025-03-31, but specific total revenue figures are not provided in this excerpt.
How do product revenues in Q1 2025 compare to Q1 2024?
The filing includes data points for 'us-gaap:ProductMember' for both 2025-01-01 to 2025-03-31 and 2024-01-01 to 2024-03-31, suggesting a comparison is available within the full document.
What is Alnylam's primary business segment as indicated by the SIC code?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to Pharmaceutical Preparations.
When was Alnylam Pharmaceuticals, Inc. previously known by another name?
The company was formerly known as ALNYLAM PHARMACEUTICALS INC, with a date of name change on 20020724.
What is the company's fiscal year end?
Alnylam Pharmaceuticals, Inc.'s fiscal year ends on 1231.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).